3355-21-3

Basic information

• Product Name: 5-Bromo-2-propyl-phenylamine
• Synonyms: 5-Bromo-2-propyl-phenylamine
• CAS NO: 3355-21-3
• Molecular Weight: 214.105
• Mol File: 3355-21-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 5-Bromo-2-propyl-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-propyl-phenylamine(3355-21-3)
• EPA Substance Registry System: 5-Bromo-2-propyl-phenylamine(3355-21-3)

Safety Data

• Hazardous Substances Data: 3355-21-3(Hazardous Substances Data)

Upstream product

• 3355-08-6 4-Bromo-2-nitro-1-propyl-benzene 
• 7732-18-5 water 
• 42411-95-0 4-propyl-3-nitroaniline 
• 24503-35-3 2,4-dinitro-1-propylbenzene 
• 103-65-1 phenylpropane 

Downstream Products

• 92425-68-8 <5-Brom-2-propyl-phenyl>-4-brom-benzolsulfonat 
• 199172-01-5 6-bromo-3-ethyl-1H-indazole 
• 1049651-71-9 1-(6-bromo-3-ethyl-1H-indazol-1-yl)ethanone 
• 56152-26-2 5-Brom-2-propyl-phenol 

Relevant articles and documents

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds of formula (I), or acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal. The invention also relates to intermediates that are useful in the preparation of the compounds of formula (I).

Substituted indazole analogs

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds o